Today we’re going to look at Jazz Pharmaceuticals (JAZZ), which specializes in treatments for narcolepsy and rare diseases. In 2012, the company merged with Azure Pharma and moved its tax domicile to Ireland. Analysts say that shift has given Jazz more room to grow. The lower corporate tax rate has reportedly helped the company maximize its cash flow and make acquisitions.